Skip to content

Immix Biopharma, Inc. IMMX Compensation and benefits

Compensation and benefits at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
Precigen logo
PrecigenPGEN
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
Sana Biotechnology logo
Sana BiotechnologySANA
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s compensation and benefits?
Immix Biopharma, Inc. (IMMX) reported compensation and benefits of $880.67K in Q1 2026.
How has Immix Biopharma, Inc.'s compensation and benefits changed year-over-year?
Immix Biopharma, Inc.'s compensation and benefits increased by 20.3% year-over-year, from $731.79K to $880.67K.
What is the long-term trend for Immix Biopharma, Inc.'s compensation and benefits?
Over 2 years (2023 to 2025), Immix Biopharma, Inc.'s compensation and benefits has grown at a 27.7% compound annual growth rate (CAGR), from $577.85K to $942.16K.